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Background: The development and application of standardised sets of outcomes to be measured and reported in
clinical trials have the potential to increase the efficiency and value of research. One of the most notable of the
current outcome sets began nearly 20 years ago: the World Health Organization and International League of
Associations for Rheumatology core set of outcomes for rheumatoid arthritis clinical trials, originating from the
OMERACT (Outcome Measures in Rheumatology) Initiative. This study assesses the use of this core outcome set by
randomised trials in rheumatology.
Methods: An observational review was carried out of 350 randomised trials for the treatment of rheumatoid
arthritis identified through The Cochrane Library (up to and including September 2012 issue). Reports of these trials
were evaluated to determine whether or not there were trends in the proportion of trials reporting on the full
set of core outcomes over time. Researchers who conducted trials after the publication of the core set were
contacted to assess their awareness of it and to collect reasons for non-inclusion of the full core set of outcomes
in the study.
Results: Since the introduction of the core set of outcomes for rheumatoid arthritis, the consistency of
measurement of the core set of outcomes has improved, although variation in the choice of measurement
instrument remains. The majority of trialists who responded said that they would consider using the core outcome
set in the design of a new trial.
Conclusions: This observational review suggests that a higher percentage of trialists conducting trials in
rheumatoid arthritis are now measuring the rheumatoid arthritis core outcome set. Core outcome sets have the
potential to improve the evidence base for health care, but consideration must be given to the methods for
disseminating their availability amongst the relevant communities.
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The selection of appropriate outcome measures is crucial
to the design of randomised trials. Outcomes need to be
relevant to patients, practitioners and policy-makers if the
findings of the research are to influence practice and fu-
ture research. Poor or inappropriate selection and meas-
urement of outcomes is not the only problem. Research
has shown that outcome reporting bias, that is, results-
based selection for publication of a subset of the original
outcome variables, is also a major problem in randomised
trials [1]. An empirical study of the impact of outcome* Correspondence: prw@liv.ac.uk
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reproduction in any medium, provided the orreporting bias in randomised trials on the results of
Cochrane systematic reviews found that this type of bias is
an ‘under-recognised problem that affects the conclusions
in a substantial proportion of Cochrane reviews’ [2].
One way to mitigate the problems described above is the
introduction of an agreed minimum set of standardised
outcomes, to be measured and reported in all trials for a
particular disease or condition, referred to as a core out-
come set (COS) [3,4].
In rheumatoid arthritis (RA), it has been common
practice since the 1950s to use a selection of traditional
measures to define the endpoints of most clinical trials,
usually including measures based on the clinician’s physical
examination, global assessment, laboratory measurementsl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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became clearer to researchers that the measures chosen
rarely included patient reported outcomes, were not com-
prehensive, some were insensitive to change, and others
measured the same phenomenon and were thus redun-
dant [5]. Furthermore, it was notable that the choice of
outcomes was variable between trials: for instance, clinical
trials of patients with RA in the USA measured different
outcomes to those conducted in Europe [6].
Following the first OMERACT (Outcome Measures in
Rheumatology) conference in 1992, and aided by meet-
ings of experts convened by the American and European
rheumatology organisations (American College of Rheuma-
tology (ACR) and European League Against Rheumatism
(EULAR)), the World Health Organization (WHO) and
International League of Associations for Rheumatology
(ILAR) in 1994 ratified a core set of outcomes for clinical
trials of symptom-modifying anti-rheumatic drugs in RA
[7]: tender joints, swollen joints, pain, physician global as-
sessment, patient global assessment, physical disability
and acute phase reactants. In trials lasting at least one
year, an additional recommendation was that radiographs
of the joints be taken to assess radiological damage.
In this paper we investigate whether outcome selection
in RA trials has changed over time, in particular whether
the RA COS is more frequently measured since the
introduction of the core set of outcomes for RA and the
publication of relevant regularity guidance for RA. We
also question lead authors of recently published RA tri-
als in the study cohort to gain a better understanding of
trialists’ awareness of the COS and to establish reasons
for non-inclusion of these outcomes in their trials.
Methods
We searched The Cochrane Library to identify all Cochrane
Reviews (up to and including September 2012 issue) that had
considered both pharmacological and non-pharmacological
interventions for the treatment of RA. Reviews were ex-
cluded if they considered only drug safety because the
focus of the current study was on measures of benefit. Re-
views were also excluded if no eligible randomised trials
were identified, or if the review was marked as ‘withdrawn’
in The Cochrane Library or was an overview of systematic
reviews. All reports for each randomised trial included
in eligible reviews were obtained for evaluation. Non-
randomised trials and trials without full publications were
excluded. Eligible trials that appeared in multiple reviews
were evaluated once.
Assessment of trial reports
For each review, a matrix was constructed [8] (http://ctrc.
liv.ac.uk/orbit/) that listed all outcomes reported in each
trial. An example outcome matrix is given in Additional file 1:
Figure S1, showing whether or not trials reported on thefull RA COS. For each core outcome, two members of the
OMERACT executive committee (MB and PT) agreed on
acceptable measurement instruments. If trial authors had
used a composite outcome measure (for example, Disease
Activity Score [9] or ACR improvement criteria [10]), all
the individual core outcomes included in the composite
were considered to have been measured, even if not repor-
ted on separately.
Evaluation of the core outcome set
Trials were grouped according to ‘topics’ as listed on
The Cochrane Library for reviews in RA. Topics were sep-
arated into pharmacological and non pharmacological in-
terventions. The former comprised disease-modifying
anti-rheumatic drugs (DMARDs), previously also known
as slow-acting anti-rheumatic drugs; symptom modifying
anti-rheumatic drugs; glucocorticoids (currently classified
as steroids on The Cochrane Library); and biologics. Non-
pharmacological interventions were alternative therapies,
assistive technology, diet, exercise, rehabilitation and sur-
gery. To assess how the measurement of core outcomes
had changed over time, we ordered the trials according to
publication date, divided them into blocks of ten and cal-
culated a moving average of the proportion reporting the
full set. Results were presented separately for pharmaco-
logical and non-pharmacological intervention types and
plotted for a period where there were a reasonable num-
ber of trials. To examine the possibility that any improve-
ment in RA COS uptake resulted from more recent trials
reporting a higher number of outcomes generally or as a
result of Food and Drug Administration [11] or European
Medicines Agency [12] regularity guidance for the treat-
ment of RA, we also produce a similar moving average for
the total number of clinical outcomes (core and non-core)
over time and denoted the points at which important
regularity guidelines for RA were first published.
For each topic, we calculated the proportion of trials
that reported on the full RA COS before and after it was
published. A decision to classify randomised trials pub-
lished up to 1994 (the year of the RA COS publication)
as ‘pre-RA COS’, and the remainder as ‘post-RA COS’,
was made a priori. We present the results for the full
outcome set (eight outcomes) for trials lasting a year or
longer, and exclude radiological damage from the assess-
ment (seven outcomes) for trials less than one year. Pat-
terns in the reporting of each individual core outcome
were also examined.
We also compared the measurement of the individual
core clinical outcomes and laboratory measurements re-
ported between the pre-RA COS and post-RA COS trial
groups for both pharmacological and non-pharmacological
interventions. For laboratory measurements, trials were
classified according to whether they measured any of
the following: acute phase reactants, haematology, bio-
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cialised immunology. The frequency of reporting of the
different acceptable measurement instruments used for
any of the core outcomes were recorded, as were any add-
itional non-core clinical outcomes.
Contact with trialists
For trials that were published post-RA COS (1995 on-
wards), the trialists were contacted via email. Trialists
were asked about their awareness of the COS during the
design stage of their trial (or relevant point of outcome
selection), whether or not the RA COS influenced their
choice of outcomes, their awareness of the COS during
final analysis and reporting, and whether or not they
would consider using the COS in future trials in this
area. Trialists not reporting on the full COS were also
asked about reasons for not using it and the consider-
ations that led to the outcomes that they did measure.
Results
Up to and including the September 2012 issue, we found
56 eligible reviews in The Cochrane Library. Eight were
excluded: four did not identify any randomised trials, two
were overviews, one focussed on safety only and one had
been withdrawn (Figure 1). Of the remaining 48 reviews,
31 focussed on a pharmacological intervention and 17 on
a non-pharmacological intervention (Figure 1).
These 48 reviews included a total of 350 randomised
trials after any exclusions, 204 investigating a pharmaco-
logical intervention and 146 non-pharmacological inter-
ventions (Figure 2). About half were published post-RA
COS (51% and 45% respectively; Figure 2).
Reporting of the rheumatoid core outcome set
The reporting of the full RA COS over time is illustrated
for both pharmacological and non-pharmacological
intervention types in Figure 3, where a clear upward
trend in the proportion of trials reporting on the full RA
COS is observed. Since 1990, there does not appear to
be much fluctuation in the total number of clinical out-
comes measured in trials. On average most trials
reported between six and seven clinical outcomes (this
assessment excluded the measurement of an acute phase
reactant as this was classified as a laboratory measurement).
A list of acceptable core outcome measurement scales ac-
cepted in this evaluation, with frequency of use, is reported
in Additional file 1: Table S1.
After the RA COS publication, marked increases were
found in the measurement of the full set of RA core out-
comes in pharmacologic interventions, especially DMARDs
(Table 1). Despite improvement in the post-RA COS
period, full RA COS reporting was generally low in
symptom-modifying interventions. Biologics were intro-
duced post-RA COS publication and most trials of theseagents reported the full outcome set. There were too few
trials in the glucocorticoids group to judge the impact. RA
COS uptake was generally lower for trials with ≥52 weeks’
follow-up because of the additional requirement to meas-
ure radiological damage. For the pharmacological in-
terventions, seven pharmacological trials of duration ≥52
weeks were classified as not reporting the full set because
they did not measure radiological damage.
In trials of alternative therapies and dietary interven-
tions, the measurement of the full RA COS increased
post-RA COS (Table 1), however this was not observed
for rehabilitation interventions. Only a few trials studied
assistive technology, exercise or surgery, and none of
these reported on the full RA COS.
For both pharmacological and non-pharmacological
interventions, most individual outcomes were measured
more frequently post-RA COS (Additional file 1: Tables S2
and S3). Tender joints, pain and physical disability were
already measured frequently pre-RA COS; the largest
increases occurred in swollen joint and both global
measurements.
Other outcome measures
Measurement of acute phase reactants (part of the RA
COS) increased post-RA COS in trials of pharmaco-
logical and non-pharmacological interventions, whereas
the number of other laboratory measurements remained
similar (Additional file 1: Table S4).
In addition to the core outcomes, it was also noted
that a number of trials frequently reported on a number
of non-core outcomes. The most frequently reported
non-core outcomes are reported in Additional file 1:
Table S5.
Contact with trialists
Pharmacological interventions
We were able to contact 72% (76 out of 105) of the au-
thors from post-RA COS trials and received responses
from 50% (38 out of 76), with similar response rates for
those trials reporting on the full RA COS (25 out of 52,
48%) and those that did not (13 out of 24, 54%). Almost
all (24 out of 25) trialists reporting the full RA COS
were aware of it during the design stage. Most (21 out of
24) said that the awareness of the RA COS directly
influenced their choice to measure these outcomes, and
that they would also consider using the full RA COS in
a new trial. Of the remaining three trialists, two felt the
outcome set had been taken over by remission criteria
and one was unlikely to lead a future trial eligible for
this evaluation.
Most of the trialists (9 out of 13) not reporting the
full RA COS were unaware of the COS during the de-
sign stage of their trial. The remaining four were aware
but did not measure the full COS for the following
Exclusions:
No randomised controlled trials 
identified  (4)
Overview (2)
Safety only (1)
Withdrawn (1)
Number of reviews included in 
evaluation: 
48
Number of reviews with 
pharmacological intervention: 
31
Number of reviews with non-
pharmacological intervention: 
17
Type of intervention: 
Alternative therapies: 2
Assistive technology: 1
Diet: 1
Exercise: 2
Rehabilitation: 9
Surgical: 2
Type of intervention:
DMARD/SAARD: 12
SMARD: 10
Glucocorticoids: 1
Biologics: 8
Number of unique rheumatoid 
arthritis reviews identified on the 
Cochrane Library 
56
•
•
•
•
•
•
•
•
Figure 1 Flow diagram of rheumatoid arthritis Cochrane systematic reviews included in study. DMARD, disease-modifying anti-rheumatic
drugs; SAARD, slow-acting anti-rheumatic drugs; SMARD, symptom-modifying anti-rheumatic drugs.
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measured but forgot to report on one of the core out-
comes, and one trial did not measure physician global as-
sessment at a time when the RA COS had been developed
but not published. All 13 trialists would consider using
the full RA COS in the design of a new trial.
Non-pharmacological interventions
We were able to contact a third (22 out of 65) of authors
from the post-RA COS group of trials by email, and re-
ceived responses from just four. One trial did report on
the full COS (publication year 2007); the trialist wasaware of the COS during the design stage of the trial
and measured the RA COS as a result, and stated they
would measure the full RA COS in future trials. The
other three trials (publication years 1999, 2001, 2003)
did not measure the full set of outcomes, with two being
unaware of the RA COS during the design stage of their
trial. The trialist who was aware of the RA COS did not
use it as they thought it was designed for drug trials.
One of the two trialists that were unaware of the COS
during the design stage would consider using the RA
COS in a future trial and the other trialist did not think
the outcomes were all that relevant in rehabilitation
Number of trials identified from 
48 Cochrane Reviews 
444
Study Exclusions:
Duplicates trials used in more than 
one review (24)
No full report available (12)
Non-RCTs: (58)
Number of trials included in 
evaluation: 
350
Number of trials with 
pharmacological intervention: 
204
Number of trials with non-
pharmacological intervention: 
146
Type of intervention 
(‘pre’ and ‘post’ RA COS):
DMARD/SAARD: Pre: 45, Post: 37
SMARD: Pre: 52, Post: 19
Glucocorticoids: Pre: 2*, Post: 10**
Biologics: Pre: 0, Post: 39
Type of intervention
(‘pre’ and ‘post’ RA COS):
Alternative therapies: Pre: 15, Post: 10
Assistive technology: Pre: 0, Post: 1
Diet: Pre: 6, Post: 8
Exercise: Pre: 5, Post: 3
Rehabilitation: Pre: 55, Post: 40
Surgical: Pre: 0, Post: 3
•
•
•
•
•
•
•
Figure 2 Evaluation of randomised controlled trials within reviews. * One duplicate trial assessed under SMARD only. ** Two duplicate trials
assessed under SMARD only. SMARD, disease-modifying anti-rheumatic drugs; SAARD, slow-acting anti-rheumatic drugs; SMARD, symptom-modifying
anti-rheumatic drugs.
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assessing disease activity.
Discussion
This study demonstrates that a community of trialists
can come together to improve the consistency of out-
comes that are measured. The trend over time for the
number of trials reporting on the RA COS (Figure 3)
was encouraging although there is still room for im-
provement. Despite the scope of the RA COS, there was
also a suggestion that the core set of outcomes were be-ing more frequently measured in RA trials that the RA
COS was not specifically designed for, for example, non-
pharmacological treatments. However, the reporting of
the full RA COS for these intervention types in general
remained low. The improvement in the measurement of
the COS over time was not due to a general increase in
the number of outcomes measured and reported in
more recent trials. This includes the number of labora-
tory measurements, which stayed stable except for acute
phase reactants (part of the COS). We acknowledge that
other influential factors may also have contributed to
Figure 3 Percentage of trials reporting on the full rheumatoid arthritis core outcome set and the average number of clinical outcomes
measured over time (10-point moving yearly average). Note: The updated European Medicines Agency guideline first came into operation in
June 2004 [12], although this was based on an earlier version adopted in 1998. This guideline is currently under further revision as from 2011. The
Food and Drug Administration guideline was first released in 1996 but was not formalised until 1999 [11]. There has been no formal revision of
this guideline since 1999.
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core outcomes. For example, the proportion of trials
reporting on the full RA COS started to rise shortly after
regulatory guidelines for RA were introduced by the
Food and Drug Administration and European Medicines
Agency. These guidelines were, however, informed by
the same organisations involved in ratifying the RA COS
(EULAR, ILAR, ACR and OMERACT). Since the publi-
cation demonstrating agreement regarding the import-
ance of these outcomes in RA trials [7], implementation
of the core set has improved.Table 1 Reporting of the core outcomes within the rheumato
Seven core outcomes (trials <52 weeks)
Intervention classification % measured (Pre-RA COS) % measured (Po
Pharmacological
DMARD/SAARD 27 (9/33) 85 (17/20)
SMARD 4 (2/50) 29 (5/17)
Glucocorticoids 100 (1/1) -
Biologics - 93 (26/28)
Non-pharmacological
Alternative therapies 15 (2/13) 88 (7/8)
Assistive technology - 0 (0/1)
Diet 20 (1/5) 57 (4/7)
Exercise 0 (0/3) 0 (0/2)
Rehabilitation 0 (0/47) 4 (1/27)
Surgery - -
DMARD, disease-modifying anti-rheumatic drugs; pre-RA COS, randomised trials pu
SAARD, slow-acting anti-rheumatic drugs; SMARD, symptom-modifying anti-rheumaUse of the RA COS was generally lower for trials that
were shorter than 52 weeks because there was an add-
itional requirement to measure radiological damage. Re-
sponses from trialists suggest this is a resource issue,
which is probably related to not only the cost of the pro-
cedure but also to the expenditure needed to obtain a
valid reading of the radiographs. Some trialists also men-
tioned that they would prefer to report on the remission
criteria as opposed to the RA COS. However, remission
is still rare in RA and so important clinical effects would
go unmeasured if the RA COS was not used.id arthritis core outcomes set
Eight core outcomes (trials ≥52 weeks)
st-RA COS) % measured (Pre-RA COS) % measured (Post-RA COS)
25 (3/12) 53 (9/17)
0 (0/2) 0 (0/2)
0 (0/1) 40 (4/10)
- 64 (7/11)
0 (0/2) 0 (0/2)
- -
0 (0/1) 100 (1/1)
0 (0/2) 0 (0/1)
0 (0/8) 0 (0/13)
- 0 (0/3)
blished up to 1994; post-RA COS, randomised trials published after 1994;
tic drugs.
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randomised controlled trials in all relevant Cochrane Re-
views published in RA that were unselected in terms of
intervention type. While we acknowledge that more tri-
als could have been identified through a primary review
of the literature, we believe that the searches carried out
by Cochrane systematic reviewers are thorough and are
likely to be a representative sample of all trials in RA.
Before carrying out the full study, we undertook a pilot
study of the 12 DMARD reviews to determine the ap-
propriateness of the methodology and to determine ac-
ceptable outcome measures and measurement scales for
each of the core outcomes. The measurement instru-
ments that were accepted were broad; the variability in
the number of methods or instruments that can be used
to measure each of the core outcomes in the RA COS is
a separate problem and was not addressed in this study.
A summary of the types of measurement instruments
that were accepted in this study and the frequency of
reporting of each measurement scale is presented in
Additional file 1: Table S1.
In further OMERACT work, the OMERACT Filter
was implemented to select applicable measurement in-
struments within the chosen core set domains. As part
of a patient perspective workshop at OMERACT 8 (2007),
fatigue was also considered an important patient outcome
in RA [13]. While this is an OMERACT recommendation,
no update of the core set has yet been ratified by either of
the professional organisations, ACR or EULAR. We found
that only 4 of the 19 trials in our dataset published since
2007 reported on fatigue.
One potential limitation is that the assessments were
carried out by one reviewer (JJK); however, the majority
of the instruments used to measure outcome in RA trials
are well defined (see Additional file 1: Table S1). Any
uncertainties in the types of outcomes measured were
referred to MB.
Barriers to the awareness of the COS still remain and
this study has highlighted that the uptake of a COS can
be limited or slow. For example, one trialist in this sam-
ple was unaware of the RA COS in 2001, despite its pub-
lication in 1994. It is important that the communities for
which a COS is developed are aware of its existence. It
was clear for many of the non-pharmacological trials
that the participants included in the trial had RA (hence
the RA COS was relevant), but the nature of the inter-
vention meant that many of the primary investigators
were not rheumatologists. It was encouraging to dis-
cover that 90% of trialists who responded and were likely
to lead a future trial for RA would consider using the
full RA COS, recognising, though, the possibility that
the non-respondents might be less likely to do so. For
example, trialists who had not reported on the full RA
COS appeared to be more likely to respond if their trialwas published closer to the 1994 publication date of the
RA COS compared with those who published more re-
cently (response rate 1995 to 2000, 57%; 2000 to 2009,
38%). This potential for response bias is important be-
cause one would expect that trials published recently
were more likely to be aware of the RA COS during the
design stage of the trial. Nevertheless, this wide-ranging
acceptance of a minimum set of core outcomes most
likely improved the consistency of research in RA, re-
duced heterogeneity between trials, and ensured that
outcomes relevant to patient care were measured in re-
search studies.
Placing these findings about the RA COS in a broader
context, a number of other COSs have been developed
across a wide range of areas of health care, examples in-
clude eczema (Harmonizing Outcome Measurements in
Eczema) [14] and paediatric asthma [15]. The Core Out-
come Measures in Effectiveness Trials (COMET) Initiative
[16] brings together researchers interested in the develop-
ment and application of COS and, as of September 2012,
the COMET database contained more than 170 references
to planned, on-going and completed work relevant to
COSs. This report provides evidence on the successful im-
plementation of a well-established COS in RA. Similar
evaluations should be carried out for COSs developed in
other therapeutic areas and the work presented here pro-
vides a template for such evaluations.
Conclusions
The adoption of a COS has the potential to increase the
consistency in outcomes measured across trials, reduce
selective reporting and ensure that trials are more likely
to measure appropriate outcomes. A COS for clinical tri-
als of SMARDS in RA was first ratified in 1994 by the
WHO and ILAR. This is the first study that has evalu-
ated the reporting of a COS in trial publications and
provides a template for evaluating COSs developed in
other therapeutic areas.
This observational review suggests that 60% to 70% of
trialists conducting trials in RA are now measuring the
RA COS. Of the trialists contacted, 90% said they would
consider measuring the RA COS if they were to lead a
new trial in RA.Additional file
Additional file 1: Figure S1. Example of a review outcome matrix
displaying the outcome information available in trial reports. Table S1:
Accepted measurement instruments for core outcomes with frequencies
of their usage across 350 intervention trials. Table S2: Reporting of the
individual core outcomes within the RA COS (pharmacological
interventions). Table S3: Reporting of the individual core outcomes
within the RA COS (non-pharmacological interventions). Table S4:
Reporting of laboratory measurements. Table S5: Non-core clinical
outcomes with frequencies of their usage across 350 intervention trials.
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